All analyses
AI analysis

Asiri Surgical Hospital PLC: research report

Fairly valuedbullishNov 9, 2026

Evidence points bullish because FY2026 profit rose 151.6% and the shares trade below book value. The catch is that operating cash conversion was only 0.33 times.

Reports without a focus are public, one per stock per day. Generation usually takes about 15 minutes, and we'll notify you when it's ready.

Why bullish

  • FY2026 net profit rose 151.6% year-on-year, supported by a higher operating margin and lower finance costs.
  • The shares trade at 7.1 times trailing earnings and 0.82 times book value, below healthcare peer medians of 12.9 times and 1.9 times respectively.

Against this. Operating cash conversion was only 0.33 times in FY2026, so much of the reported operating profit had not arrived as cash.

Operating margin
18.1%
latest quarter
Net margin
15.4%sector 13.0%
from 12.1% a year earlier, revenue +17.6%
Return on equity
12.0%
twelve months to Sep 30, 2026, unaudited
P/E
7.0sector 11.8
earnings Rs 1.84 per share, year to Sep 2026
P/B
0.83sector 1.36
book Rs 15.34 per share
Dividend yield
0.00%sector 0.00%
trailing twelve months

Current figures, updated daily from filings to Sep 30, 2026. The report below was written on Nov 9, 2026. Sector figures are the median of 6 listed companies in the same sector.

Overview

Asiri Surgical Hospital operates a specialist private hospital offering surgical, diagnostic and post-operative care across a range of disciplines. The recent record is of modest revenue growth translating into faster profit growth, but cash generation has lagged accounting earnings.

The market-wide valuation classification is fairly valued, yet the assessment ends bullish because the earnings recovery, lower debt burden and unusually low valuation relative to both peers and the company's own history outweigh that neutral starting point.

Price performance

At LKR 11.40 on 6 November 2026, AMSL had fallen 25.7% over three months, against a 0.6% decline in the ASPI. The share sits just 7.9% up from its 52-week low, while both recent volatility and trading volume are below its own one-year norms.

Its three-year record is four falls of 15% or more in three years, the deepest 64%, which has not yet recovered. Liquidity is limited: median daily turnover was LKR 1.6 million, and a LKR 1 million order is about 62% of what trades on a typical day, a large part of a day's trading.

Valuation

The shares trade on a P/E of 7.1 times, meaning LKR 7.10 is paid for every LKR 1 of trailing profit, versus the healthcare peer median of 12.9 times. P/B is 0.82 times, or 82 cents for each rupee of net assets, versus a 1.9 times peer median; trailing ROE was 11.5%, so the below-peer book multiple is not being demanded by weak reported returns.

Against its own record, the P/B is cheaper than 98% of days since February 2012 and the P/E cheaper than 82% of days. No sector-percentile comparison is provided. There is no current dividend yield and no dividend is on record in the last two years.

A buyer at this price is relying on earnings that are not dominated by the latest result: the June quarter supplied 23.2% of trailing EPS, and applying its year-ago net margin would still leave the P/E at 7.1 times.

News and sentiment

Direct coverage is thin, with three material articles in the past 90 days, comprising one positive and two negative items. There was no company news in the last 30 days despite the sharp three-month share-price fall.

The most material linked report, published on 17 August, said a tax dispute involving Asiri Surgical Hospital was under appeal within Softlogic Holdings' wider results coverage. The report does not quantify the potential financial exposure for AMSL.

Financials

In the June 2026 quarter, revenue grew 7.4% year-on-year and net profit grew 11.6%, so profit rose faster than sales. Gross margin was unchanged at 43.2% versus 43.2% a year earlier, while net margin improved to 11.1% from 10.7%. The operating-profit line is unavailable for the latest June quarter, so operating margin cannot be compared; it was 17.3% in June 2025.

June gross margin was the second-best of the last six comparable June quarters, whereas net margin ranked fourth of six, showing that the stronger gross outcome did not fully carry through to the bottom line. The latest filing is on a group basis and is comparable with the prior June quarter.

For the audited year to March 2026, net profit reached LKR 940 million after rising 151.6% from the prior year. Minority shareholders received 13.4% of that year's group profit, so group net profit is larger than the profit attributable to the ordinary shares being valued. No newer company results have been reported in the news, so the June filing remains the latest financial evidence.

Risks

The main financial risk is weak conversion of profit into cash. FY2026 operating cash flow was only 0.33 times operating profit and free cash flow was negative LKR 95 million, meaning reported profit did not translate fully into cash after capital spending.

Debt was LKR 1.8 billion at March 2026, equal to 24.2% of equity attributable to owners. Interest cover improved to 4.78 times, meaning operating profit covered the interest bill nearly five times, but the current ratio slipped to 1.09 times: assets expected to turn into cash within a year, including receivables and supplies, only narrowly exceeded bills due within that year.

The wider market backdrop as at 9 November included a 100-basis-point policy-rate increase and higher fuel prices. These are operating-environment risks for a hospital business, but the supplied data does not quantify their effect on AMSL.

Outlook

As at 9 November 2026, the September 2026 interim quarter was due within the exchange's expected 2 to 14 November filing window. That filing is the next specific event that can confirm whether revenue growth, margins and cash generation have held after June, or whether the earnings recovery has weakened.

The available data cannot quantify the financial outcome of the tax dispute reported as under appeal, nor does it provide terms for any current corporate action. There are no confirmed corporate actions or dividends scheduled.

About this report. Generated on Nov 9, 2026 from market data up to Nov 6, 2026, 3 material news articles over 90 days and financials to Jun 30, 2026, and scored 58 of 100 on value (fairly valued) when it was written. Every figure is drawn from EquityLK's own data on this company. AI research can contain errors, so treat it as a starting point, not investment advice.

Previous reports